RUXOLITINIB

Brand name:

• Jakavi®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED

Condition/indication:
(therapeutic use)

• Chronic Graft vs Host Disease

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to listing (Early Resolution Pathway)

Comment:

--

Other PBAC consideration:

• RUXOLITINIB
• RUXOLITINIB

Submission received for:

November 2022 PBAC meeting

Opportunity for consumer comment:

Open 27/07/2022 and close 21/09/2022 (see PBS Website)

PBAC meeting:

Held on 02/11/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

28/11/2022

Lodgement of required documentation:

14/12/2022

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 04/01/2023

Status:

Finalised

Government processes:

Commenced on 05/01/2023

Medicine listed on the PBS:

01/04/2023 (see PBS schedule)